Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · September 12, 2023

Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Patients With Diabetic Kidney Disease

Circulation

 

Additional Info

Disclosure statements are available on the authors' profiles:

Circulation
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial
Circulation 2023 Aug 22;148(8)651-660, JL Januzzi, R Mohebi, Y Liu, N Sattar, HJL Heerspink, E Tefera, M Vaduganathan, J Butler, Y Yavin, J Li, CA Pollock, V Perkovic, B Neal, MK Hansen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading